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Cadaveric Hepatocytes Repopulate Diseased Livers: Life After Death
See “Therapeutic liver reconstitution with mu-
rine cells isolated long after death,” by Erker L,
Azuma H, Lee AY, et al, on page 1019.
Presently, the only effective treatment for liver failureis solid organ transplantation. Although this ap-
proach is highly successful, it is limited by the short
supply of donor organs. As such there is an imperative
need to develop alternative therapies, such as cellular
transplantation, to treat or “bridge” patients until a suit-
able organ can be sourced. Cellular therapy in animal
models using adult human hepatocytes has demon-
strated high repopulation efficiency with restoration of
functional parenchyma1 and may represent effective
treatment for liver insufficiency as well as inherited met-
abolic liver disease.2 Although this strategy is promising,
it is likewise limited by donor organ availability.
One potential pathway to circumvent this problem
would be to expand hepatocytes ex vivo in culture. Un-
fortunately, ex vivo hepatocytes are notoriously unstable
and begin to dedifferentiate upon isolation, even in the
presence of complex growth media.3 Immortalization
strategies have therefore been applied to primary hepa-
tocytes in an attempt to overcome this problem but have
remained unsuccessful.4 In addition, such an approach
might create added complexity to direct utility in the
clinic because genetic modification to achieve a prolifer-
ative state may result in a failure of contact inhibition
and self-limiting proliferation in vivo. Because of the
intrinsic problems with primary human hepatocytes sev-
eral groups have focused on the role that stem cell pop-
ulations might have in the production of large amounts
of human hepatocytes for therapeutic purposes. The fetal
and the adult liver provide ideal systems in which to
purify potential stem cell populations. However, these
populations are low in number, thereby making their
isolation, purification, and large scale expansion chal-
lenging.5
More recently, there has been an emphasis on gen-
erating hepatocytes from pluripotent stem cell popu-
lations that are amenable to large scale production.
The generation of hepatocytes from human embryonic
stem cells (hESCs) and induced pluripotent stem cells
(iPSCs) has been demonstrated in vitro.6–10 Moreover,
iPSC technology11,12 has allowed the creation of an
autologous pluripotent stem cell population that has a
number of advantages.13 Although iPSC technology is
promising, there are a number of significant impedi-
ments before clinical implementation.13 This holds
true also for hESCs with the recent decision by the
Food and Drug Administration to put in abeyance the
first hESC safety trial.14
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Problems with pluripotent stem cell derived hepato-
cyte transplantation have been also observed in vivo. The
most advanced study to date has employed a mature
population of hepatocytes for in vivo studies. Although
this population of cells eliminated the development of
teratomas or tumors in the liver, recipient animals devel-
oped peritoneal tumors,7 demonstrating the need for
improved stem cell–derived resources before safe clinical
deployment. Therefore, the use of cell-based therapies
from pluripotent stem cell–derived hepatocytes in rou-
tine clinical practice is not imminent. However, there are
a number of near term gains using this technology that
have important roles to play in medicine; extracorporeal
strategies to bridge patients until liver transplantation
or promote endogenous organ repair and the develop-
ment of safer testing platforms for drug testing. There-
fore, there is a major drive to find reliable sources of
pluripotent stem cell–derived hepatocytes to meet this
demand.13
Given the current safety concerns with transplanting
pluripotent stem cell derived hepatocytes, the study by
Erker et al15 in this issue of GASTROENTEROLOGY is of great
interest to the field. The study provides evidence that
cadaveric liver tissue possesses clinical potential for ther-
apeutic liver repopulation, radically changing the way in
which we view the utility of this type of liver tissue.15
Previously, non–heart-beating donors have been consid-
ered as a source of transplantable hepatocytes, but only if
the livers were harvested under controlled conditions
within 45 minutes of death.16 Erker et al15 digested livers,
up to 27 hours post mortem, purifying cells suitable for
transplantation, which was nearly as efficient as with
freshly isolated hepatocytes. Moreover, Erker et al15 dem-
onstrated also that a similar type of cell population could
be isolated from human resected liver tissue and could
therefore be a potential source of hepatocytes for treating
human liver disease (Figure 1). This is very important
given the current shortage of transplantable human
hepatocytes and may facilitate the development of novel
treatment strategies that was previously inconceivable.
Although this study demonstrates enormous potential,
there are some issues that need to be addressed in future
studies before this technology can be safely deployed in
the clinic. The hepatocyte population had a selective
advantage in the described animal model. Therefore,
questions remain about the ability of cadaveric hepato-
cytes to repopulate livers in an environment where the
cells do not have a selective advantage and/or are exposed
to inflammatory mediators in response to drug-, alcohol-,
or viral-induced liver injury.
In conclusion, this study represents a vital step forward
toward the use of cadaveric hepatocytes in the clinic. This
study will undoubtedly stimulate interest in the utility of
human livers from unanticipated deaths and emphasizes
there is 1 solution to the challenge of generating high-
fidelity human hepatocytes. Moreover, this study rein-
forces the notion that different methods of deriving
human hepatocytes may suit differing clinical scenarios.
As such, we are looking forward to future studies assess-
ing the performance of human cadaveric hepatocytes in
immunocompromised FAH/ mice and immune com-
promised models of acute and chronic liver injury.
DAVID C. HAY




1. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human
hepatocytes in Fah(-/-)/Rag2(-/-)/Il2rg(-/-) mice. Nature Biotech-
nology 2007;25:903–910.
2. Zern MA. Cell transplantation to replace whole liver transplanta-
tion. Gastroenterology 2009;136:767–769.
3. Sharma R, Greenhough S, Medine CN, et al. Three-dimensional
culture of human embryonic stem cell derived hepatic endoderm
and its role in bioartificial liver construction. J Biomed Biotechnol
2010;2010:236147.
4. Delgado JP, Parouchev A, Allain JE, et al. Long-term controlled
immortalization of a primate hepatic progenitor cell line 347 after
Simian virus 40 T-Antigen gene transfer. Oncogene 2005;24:
541–551.
5. Czyz J, Wiese C, Rolletschek A, et al. Potential of embryonic and
adult stem cells in vitro. Biol Chem 2003;384:1391–1409.
6. Hay DC, Fletcher J, Payne C, et al. Highly efficient differentiation
of hESCs to functional hepatic endoderm requires ActivinA and
Wnt3a signaling. Proc Natl Acad Sci U S A 2008;105:12301–
12306.
Figure 1. Cadaveric hepatocytes efficiently repopulate diseased livers.
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